secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2023-06-05T23:59:59+00:00
Accession:  0000950170-23-026234
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics enters exclusive worldwide license with Celltrion for oral adalimumab biosimilar
--------------------------------------------------------------------------------

- Rani obtains exclusive, worldwide, royalty-free license to Celltrion IP for oral adalimumab biosimilar via Rani's delivery technology.
- Celltrion will exclusively supply adalimumab biosimilar to Rani, with limited alternative sourcing rights if supply is disrupted.
- Rani has sole manufacturing, development, and commercialization rights; Celltrion gets right of first negotiation after Phase 1 data.
- Celltrion may terminate if development milestones not met; Rani can terminate for convenience with notice.
- No financial terms disclosed; agreement covers IP ownership and mutual indemnification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023026234/0000950170-23-026234-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023026234/rani-20230601.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-026234

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer